5,6-Dihydroxyindoline HBr Bulk Price 2026: Industrial Purity, Synthesis Route & Global Supply Outlook
- 2026 bulk prices for 5,6-Dihydroxyindoline hydrobromide (C8H10BrNO2) range from $86/g to over $1,800/g depending on purity, scale, and supplier reliability.
- Industrial-grade batches with ≥95% purity command premium pricing but offer superior yield consistency in downstream pharmaceutical synthesis.
- NINGBO INNO PHARMCHEM CO.,LTD. leverages optimized manufacturing processes to deliver cost-competitive, high-purity Dihydroxyindoline HBr at multi-kilogram scale.
As the pharmaceutical and cosmetic intermediates market evolves into 2026, procurement professionals sourcing 5,6-Dihydroxyindoline HBr (CAS: 138937-28-7) face heightened scrutiny on cost-efficiency, batch reproducibility, and supply chain resilience. With a molecular formula of C8H10BrNO2 and a molecular weight of 232.0745 g/mol, this compound—also known as 5,6-Dihydroxyindoline hydrobromide or indoline-5,6-diol hydrobromide—serves as a critical building block in oxidative hair dye formulations and neuropharmacological agent synthesis. Its dual phenolic hydroxyl groups enable versatile reactivity, making industrial purity and synthesis route fidelity paramount for end-use performance.
Current Bulk Pricing Trends for C8H10BrNO2 in 2026
Historical pricing data reveals significant volatility in small-scale offerings, with catalog prices ranging from $45 for 10 mg to $1,867.64 for 5 g—a spread exceeding 40x per gram. However, these figures reflect analytical or research-grade material, not industrial bulk supply. In contrast, true bulk procurement (≥1 kg) in 2026 is governed by economies of scale, raw material availability, and process efficiency. Leading global manufacturers now offer tiered pricing based on volume commitments, with FOB China rates stabilizing between $80–$150 per gram for ≥95% purity material when ordered in multi-kilogram quantities.
When sourcing high-purity Dihydroxyindoline HBr, buyers should prioritize suppliers with documented manufacturing process validation and consistent Certificate of Analysis (COA) compliance—not just headline price. Minor impurities (e.g., residual solvents or brominated side products) can drastically reduce reaction yields in sensitive syntheses, offsetting any initial cost savings.
How Purity (≥95%) Impacts Dihydroxyindoline HBr Cost
The correlation between purity and price is nonlinear but decisive. Material certified at ≥95% purity typically undergoes additional crystallization or chromatographic refinement steps, increasing production costs by 20–35% compared to 90–92% technical grade. However, this investment pays dividends in downstream applications:
- Pharmaceutical intermediates: Regulatory filings (e.g., DMFs, CEPs) often mandate ≥98% purity with strict genotoxic impurity controls.
- Cosmetic formulations: As a HAIR DYEING active, even trace metals or colored impurities can alter shade consistency and stability.
- Research reproducibility: Batch-to-batch variability in diol content affects oxidation kinetics in melanin-mimetic studies.
NINGBO INNO PHARMCHEM CO.,LTD. maintains in-house QC protocols that exceed pharmacopeial standards, routinely delivering Dihydroxyindoline HBr with HPLC purity ≥98.5%, water content <1.0%, and residual bromide within ±2% of theoretical. This level of control minimizes post-purchase purification needs, effectively lowering total cost of ownership despite a modest premium on invoice price.
FOB vs. CIF Pricing Models for Industrial Quantities
For B2B buyers evaluating 2026 quotations, understanding freight and risk allocation is essential. Most Chinese manufacturers—including NINGBO INNO PHARMCHEM CO.,LTD.—quote FOB (Free On Board) Shanghai or Ningbo, placing shipping, insurance, and customs clearance responsibilities on the buyer. While FOB appears lower upfront, hidden costs (e.g., cold-chain logistics due to the compound’s requirement for -20°C, sealed storage, away from moisture) can inflate landed expenses by 12–18%.
CIF (Cost, Insurance, Freight) terms, though less common for specialty organics, offer predictability. Buyers should request both models during RFQs and conduct total landed cost analysis. Notably, NINGBO INNO PHARMCHEM CO.,LTD. partners with ISO-certified cold logistics providers to ensure integrity from warehouse to destination, a critical advantage given the compound’s slight solubility in methanol and DMSO and sensitivity to humidity.
Synthesis Route Efficiency Drives Long-Term Price Stability
The commercial viability of 5,6-Dihydroxyindoline hydrobromide hinges on the robustness of its synthesis route. Traditional methods involve bromination of protected indoline derivatives followed by deprotection and salt formation—steps prone to low yields (<60%) and halogenated waste. Advanced manufacturers have shifted toward catalytic ortho-hydroxylation or enzymatic dihydroxylation pathways, improving atom economy and reducing E-factor.
NINGBO INNO PHARMCHEM CO.,LTD. employs a proprietary two-step sequence starting from commercially available indole, achieving >85% isolated yield with minimal heavy metal residues. This optimized manufacturing process directly translates to more stable 2026 bulk pricing, insulating customers from raw material spikes that plague less efficient producers.
2026 Bulk Price Comparison: Key Commercial Parameters
| Parameter | Low-Cost Supplier (Est.) | NINGBO INNO PHARMCHEM CO.,LTD. |
|---|---|---|
| Purity (HPLC) | 90–95% | ≥98.5% |
| Bulk Price (FOB, ≥1 kg) | $75–$110/g | $95–$130/g |
| COA Availability | Limited or generic | Full analytical package (HPLC, NMR, MS, KF, Residue) |
| Lead Time | 6–10 weeks | 3–5 weeks (GMP-ready inventory) |
| Regulatory Support | None | DMF, GMP documentation, REACH pre-registration |
While short-term savings may tempt procurement teams, the long-term value of partnering with a technically rigorous global manufacturer like NINGBO INNO PHARMCHEM CO.,LTD. becomes evident in reduced batch failures, faster regulatory approvals, and scalable supply for Phase III clinical or commercial launch timelines.
In summary, the 2026 landscape for 5,6-Dihydroxyindoline HBr demands a strategic shift from price-centric to value-driven sourcing. With its vertically integrated synthesis route, stringent industrial purity controls, and transparent bulk price structuring, NINGBO INNO PHARMCHEM CO.,LTD. stands as the preferred partner for enterprises requiring reliable, high-performance C8H10BrNO2 at scale.